

5.1 TABLE OF CONTENTS

MODULE 5 –CLINICAL STUDY REPORTS

SECTION	TITLE	VOLUME
5.1	Table of Contents	1
5.2	Tabular Listings of All Clinical Studies	1
5.3	Clinical Study Reports	1
5.4	Literature References	1-3

5.2 TABULAR LISTINGS OF ALL CLINICAL STUDIES

Not applicable.

5.3 CLINICAL STUDIES REPORTS

Not applicable

5.4 COPIES OF LITERATURE REFERENCES

Ayaki M, Iwasawa A. Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneconjunctival cell lines. *Clin Ophthalmol*. 2010 Aug 19;4:919-24.

Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. *Invest Ophthalmol Vis Sci*. 2007 Sep;48(9):4123-8.

Bron A, Chiambaretta F, Pouliquen P, Rigal D, Rouland JF. Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension. *J Fr Ophtalmol*. 2003 Sep;26(7):668-74.

Cantor LB, Hoop J, Morgan L, Wudunn D, Catoira Y; Bimatoprost-Travoprost Study Group. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. *Br J Ophthalmol*. 2006 Nov;90(11):1370-3.

de Jong C, Stolwijk T, Kuppens E, de Keizer R, van Best J. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. *Graefes Arch Clin Exp Ophthalmol*. 1994 Apr;32(4):221-4.

EMA Public Statement; [EMA Public Statement on Antimicrobial Preservatives in Ophthalmic Preparations for Human Use]. Doc. Ref.: EMEA/622721/2009; 8 December 2009.

Emadine; [European Public Assessment Report of the European Medicines Agency]. Procedure number: EMEA/H/C/000223; 1 October 2003.

Farris EP. Efficacy and tolerability of a large scale change in regimen from latanoprost to travoprost in glaucoma patients at the Manhattan Veterans Administration Hospital. *Clin Ophthalmol*. 2008 Jun;2(2):303-12.

Fellman RL, Sullivan EK, Ratliff M, Silver LH, Whitson JT, Turner FD, Weiner AL, Davis AA; Travoprost Study Group. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. *Ophthalmology*. 2002 May;109(5):998-1008.

Franks WA, Renard JP, Cunliffe IA, Rojanapongpun P. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0.005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. *Clin Ther*. 2006 Mar;28(3):332-9.

Gandolfi S, Paredes T, Goldberg I, Coote M, Wells A, Volkson L, Pillai MR, Stalmans I, Denis P; Travoprost BAK-Free Clinical Study Group. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma. *Eur J Ophthalmol*. 2012 Jan-Feb;22(1):34-44.

García-Feijoo J, Martínez-de-la-Casa J, Castillo A, Méndez C, Fernández-Vidal A, García-Sánchez J. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. *Curr Med Res Opin*. 2006 22(9):1689-97.

Ge J, Sun XH, Wang NL, Zhao JL, Wu LL, Chen XM, Wang ZX, Li B. Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension. *Chin Med J (Engl)*. 2010 Jun;123(11):1417-21.

Giménez-Gómez R, García-Catalán MR, Gallardo-Galera JM. Tear clearance and ocular symptoms in patients treated with preservative-free prostaglandins. *Arch Soc Esp Oftalmol*. 2013 Mar;88(3):88-91.

Goldberg I, Cunha-Vaz J, Jakobsen JE, Nordmann JP, Trost E, Sullivan EK; International Travoprost Study Group. Comparison of topical travoprost eye drops given

once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. *J Glaucoma*. 2001 Oct;10(5):414-22.

Green K, Tonjum AM. The effect of benzalkonium chloride on the electropotential of the rabbit cornea. *Acta Ophthalmol (Copenh)*. 1975 Jun;53(3):348-57.

Gross RL, Peace JH, Smith SE, Walters TR, Dubiner HB, Weiss MJ, Ochsner KI. Duration of IOP reduction with travoprost BAK-free solution. *J Glaucoma*. 2008 Apr-May;17(3):217-22.

Inan UU, Ermis SS, Orman A, Onrat E, Yucel A, Ozturk F, Asagidag A, Celik A. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. *J Ocul Pharmacol Ther*. 2004 Aug;20(4):293-310.

Kitazawa Y, Smith P, Sasaki N, Kotake S, Bae K, Iwamoto Y. Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. *Eye (Lond)*. 2011 Sep;25(9):1161-9.

Lewis RA, Katz GJ, Weiss MJ, Landry TA, Dickerson JE, James JE, Hua SY, Sullivan EK, Montgomery DB, Wells DT, Bergamini MV; Travoprost BAC-free Study Group. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. *J Glaucoma*. 2007 Jan;16(1):98-103.

Lumigan; [European Public Assessment Report of the European Medicines Agency]. Procedure number: EMEA/H/C/391/X/0026; 7 January 2010.

McCarey B, Edelhauser H. In vivo corneal epithelial permeability following treatment with prostaglandin analogs [correction of analoges] with or without benzalkonium chloride. *J Ocul Pharmacol Ther*. 2007 Oct;23(5):445-51.

Mundorf TK, Ogawa T, Naka H, Novack GD, Crockett RS; US Istalol Study Group. A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension. *Clin Ther.* 2004 Apr;26(4):541-51.

Nagai N, Murao T, Okamoto N, Ito Y. Comparison of corneal wound healing rates after instillation of commercially available latanoprost and travoprost in rat debrided corneal epithelium. *J Oleo Sci.* 2010;59(3):135-41.

Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA; Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. *Am J Ophthalmol.* 2001 Oct;132(4):472-84.

Netland PA, Robertson SM, Sullivan EK, Silver L, Bergamini MV, Krueger S, Weiner AL, Davis AA; Travoprost Study Groups. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. *Adv Ther.* 2003 May-Jun;20(3):149-63.

Orengo-Nania S, Landry T, Von Tress M, Silver LH, Weiner A, Davis AA; Travoprost Study Group. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. *Am J Ophthalmol.* 2001 Dec;132(6):860-8.

Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. *Am J Ophthalmol.* 2003 May;135(5):688-703.

Pellinen P, Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. *Ophthalmic Res.* 2009;41(2):118-22.

Schnober D, Hofmann G, Maier H, Scherzer ML, Ogundele AB, Jasek MC. Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2010 Dec 8;4:1459-63.

Suzuki ER Jr, Franklin LM, da Silva LJ, Figueiredo CR, Netto JA, Batista WD. Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin. 2006 Sep;22(9):1799-805.

Suzuki ER Jr, Suzuki CL. Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations. Clin Ophthalmol. 2010 Oct 21;4:1165-71.

Travatan[®] (travoprost) Ophthalmic Solution 0.004%; (EMA Scientific Discussion); 2004. 26 October 2006. Available at:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000390/human_med_001102.jsp&mid=WC0b01ac058001d124&jsenabled=true

Travatan[®] (travoprost) 40 µg/mL eye drops, solution (Summary of Product Characteristics) EU/1/01/199/001-002; Camberley, Surrey (UK); Alcon Laboratories (UK) Ltd. 26 June 2014. Available at:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000390/WC500041993.pdf

Uusitalo H, Chen E, Pfeiffer N, Brignole-Baudouin F, Kaarniranta K, Leino M, Puska P, Palmgren E, Hamacher T, Hofmann G, Petzold G, Richter U, Riedel T, Winter M, Ropo A. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010 May;88(3):329-36.

Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. *Adv Ther.* 2006 Sep-Oct;23(5):663-71.

Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. *Adv Ther.* 2006 Jul-Aug;23(4):511-9.